⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37649965 | 1.00 | — | — | |
| SCHEMBL2238411 | 0.74 | KMO (0.44) | — | |
| SCHEMBL3632318 | 0.73 | — | — | |
| SCHEMBL1187140 | 0.73 | — | — | |
| SCHEMBL109350 | 0.73 | — | — | |
| SCHEMBL1629251 | 0.73 | — | — | |
| SCHEMBL4448243 | 0.73 | — | — | |
| SCHEMBL3938053 | 0.73 | — | — | |
| SCHEMBL30362276 | 0.73 | — | — | |
| SCHEMBL27234444 | 0.72 | KMO (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217336-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025128834-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4433470-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | Blueprint Medicines Corporation (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-118265706-A | CDK2 inhibitors and methods of making and using the same | 缆图药品公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| CN-101646673-A | 3-amino-pyrrolo [3, 4-C ] pyrazole-5 (1H,4H,6H) carbaldehyde derivatives as PKC inhibitors | PFIZER US | 2010-02-10 | — | — | CN | disclosed |
| EP-2118112-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | Pfizer Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008096260-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1838718-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2006072831-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2006-07-13 | — | — | WO | disclosed |